Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs LY 3202626 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms NAVIGATE-AD
- Sponsors Eli Lilly
- 11 Aug 2017 Planned number of patients changed from 500 to 380.
- 11 Aug 2017 Planned End Date changed from 1 Aug 2019 to 1 Jun 2019.
- 11 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Jun 2019.